Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 December 2006Website:
http://www.medicinova.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 32 min agoDividend
Analysts recommendations
Institutional Ownership
MNOV Latest News
Company to rededicate efforts toward updating stakeholders on corporate vision, strategy, and ongoing activities
LA JOLLA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the prevention of metastasis in various cancers including pancreatic cancer, lung cancer, breast cancer, colorectal cancer, melanoma, and ovarian cancer.
LA JOLLA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova's collaborator, Gilbert Youssef, M.D. at Harvard Medical School, Attending Physician, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital, presented new data and results of a Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma (GBM) at the American Society of Clinical Oncology (ASCO) Annual meeting 2024 held May 31- June 4th in Chicago, IL.
LA JOLLA, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova conducted two poster presentations at the 92nd European Atherosclerosis Society (EAS) 2024 Congress held online May 26-29, 2024.
Medicinova Inc (NASDAQ:MNOV) stock started Wednesday on the front foot boosted by a patent award in Europe. The European Patent Office has given protection to the company's asset MN-001 (tipelukast) for the treatment of scleroderma and/or systemic sclerosis.
What type of business is MediciNova?
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
What sector is MediciNova in?
MediciNova is in the Healthcare sector
What industry is MediciNova in?
MediciNova is in the Biotechnology industry
What country is MediciNova from?
MediciNova is headquartered in United States
When did MediciNova go public?
MediciNova initial public offering (IPO) was on 08 December 2006
What is MediciNova website?
https://www.medicinova.com
Is MediciNova in the S&P 500?
No, MediciNova is not included in the S&P 500 index
Is MediciNova in the NASDAQ 100?
No, MediciNova is not included in the NASDAQ 100 index
Is MediciNova in the Dow Jones?
No, MediciNova is not included in the Dow Jones index
When does MediciNova report earnings?
The next expected earnings date for MediciNova is 09 August 2024